

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation

Our Company is an exempted company with limited liability incorporated in the Cayman Islands under the Cayman Companies Act on September 30, 2020. Our registered office address is Tricor Services (Cayman Islands) Limited, Second Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands. Accordingly, our Company’s corporate structure and Memorandum and Articles are subject to the relevant laws of the Cayman Islands. A summary of our Memorandum and Articles is set out in the section headed “Summary of the Constitution of our Company and Cayman Islands Company Law” in Appendix III to this document.

Our registered place of business in Hong Kong is at 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong. We were registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on January 3, 2022 with the Registrar of Companies in Hong Kong. Ms. Hui Yin Shan (許燕珊) and Ms. Yuen Wing Yan Winnie (袁穎欣) have been appointed as the authorized representative of our Company for the acceptance of service of process in Hong Kong. The address for service of process in Hong Kong is at 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong.

2. Changes in the share capital of our Company

Our Company was incorporated in the Cayman Islands with limited liability on September 30, 2020. As of the date of our Company’s incorporation, the authorized share capital of our Company was US\$50,000.00 divided into 500,000,000 ordinary Shares with a par value of US\$0.0001 each.

Save as disclosed in the section headed “History, Reorganization and Corporate Structure” in this document, there has been no alteration in the share capital of our Company since its incorporation.

3. Changes in the share capital of our subsidiaries

Our Company’s subsidiaries are referred to in the Accountants’ Report in Appendix I to this document. Save for the subsidiaries mentioned above, in the Accountant’s Report and the section headed “History, Reorganization and Corporate Structure” in this document, our Company has no other subsidiaries.

The following changes in the share capital of our subsidiaries have taken place within the two years immediately preceding the date of this document:

Shanghai Shenjing

On August 18, 2021, the registered capital of Shanghai Shenjing was increased from US\$45.0 million to US\$75.0 million.

MP NeuroTech Shanghai

On August 10, 2020, the registered capital of MP NeuroTech Shanghai was increased from RMB53.5 million to RMB63.53125 million.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

On May 11, 2021, the registered capital of MP NeuroTech Shanghai was increased from RMB63.53125 million to RMB163.53125 million.

Shentu Medical

On November 13, 2020, the registered capital of Shentu Medical was increased from RMB1 million to RMB60 million.

MP NeuroTech BVI

On November 11, 2020, the share capital of MP NeuroTech BVI was increased from US\$1.00 to US\$100.99.

On May 20, 2021, the share capital of MP NeuroTech BVI was increased from US\$100.99 to US\$17,800,100.99 (increased by RMB115,000,000.00 in USD Equivalent).

On August 25, 2021, the share capital of MP NeuroTech BVI was increased from US\$17,800,100.99 to US\$42,702,569.91.

MP NeuroTech HK

On November 11, 2020, the share capital of MP NeuroTech HK was increased from US\$1.00 to US\$100.99.

On May 20, 2021, the share capital of MP NeuroTech HK was increased from US\$100.99 to US\$17,800,100.99.

On August 25, 2021, the share capital of MP NeuroTech HK was increased from US\$17,800,100.99 to US\$42,702,569.91.

Save as disclosed above, there has been no alteration in the share capital of any of our subsidiaries within the two years immediately preceding the date of this document.

4. Resolutions of the Shareholders of our Company dated [●]

Written resolutions of the Shareholders of our Company [were passed] on [●], pursuant to which, among others:

- (a) [each unissued and issued share in the share capital of our Company of a par value of US\$0.0001 each was subdivided into [five] shares of a par value of US\$[0.00002] each such that following such subdivision, the authorized share capital shall be US\$50,000 divided into: (i) [2,392,439,740] ordinary Shares of a par value of US\$[0.00002] each; (ii) [58,795,625] Series A-1 Preferred Shares of a par value of US\$[0.00002] each; and (iii) [48,764,635] Series A-2 Preferred Shares of a par value of US\$[0.00002] each;
- (b) conditional on (1) the Stock Exchange granting the [REDACTED] of, and permission to [REDACTED], the Shares in issue and to be issued pursuant to the [REDACTED] (including upon the re-designation of the Series A Preferred Shares) and such [REDACTED] and permission not subsequently having been revoked prior to the commencement of [REDACTED] the Shares on

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

the Stock Exchange; (2) the [REDACTED] having been determined; (3) the obligations of the [REDACTED] under the [REDACTED] becoming unconditional and not being terminated in accordance with the terms of the [REDACTED] or otherwise, in each case on or before such dates as may be specified in the [REDACTED]; and (4) the [REDACTED] having been duly executed by the [REDACTED] and our Company:

- (i) the [REDACTED] (including the grant of the [REDACTED]) was approved, and the proposed allotment and issue of the [REDACTED] under the [REDACTED] were approved, and our Board was authorized to determine the [REDACTED] for, and to allot and issue the [REDACTED];
- (ii) the [REDACTED] was approved and our Directors were authorized to effect the same and to allot and issue up to [REDACTED] Shares upon the exercise of the [REDACTED];
- (iii) a general mandate was given to our Directors to exercise all powers of our Company to allot, issue and deal with Shares or securities convertible into Shares and to make or grant offers, agreements or options (including any warrants, bonds, notes and debentures conferring any rights to subscribe for or otherwise receive Shares) which might require Shares to be allotted and issued or dealt with subject to the requirement that the aggregate nominal value of our Shares so allotted and issued or agreed conditionally or unconditionally to be allotted and issued, otherwise than by way of the [REDACTED], rights issue or pursuant to the exercise of any subscription rights attaching to any warrants which may be allotted and issued by our Company from time to time or allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the Articles of Association on a specific authority granted by our Shareholders in a general meeting, shall not exceed the sum of (i) 20% of the aggregate nominal value of our Shares in issue immediately following the completion of the [REDACTED] (but excluding any Shares which may be issued pursuant to the exercise of the [REDACTED]); and (ii) the aggregate nominal amount of the share capital of our Company purchased by our Company pursuant to the authority granted to our Directors as referred to in (iv) below;
- (iv) a general mandate (the "**Repurchase Mandate**") was given to our Directors to exercise all powers of our Company to repurchase its own Shares on the Stock Exchange or on any other stock exchange on which the securities of our Company may be [REDACTED] and which is recognized by the SFC and the Stock Exchange for this purpose, in accordance with all applicable laws and the requirement of the Listing Rules such number of Shares as will represent up to 10% of the aggregate nominal value of our Shares in issue immediately following the completion of the [REDACTED];
- (v) the general mandate as mentioned in paragraph (iii) above was extended by the addition to the aggregate nominal value of our Shares which may be allotted and issued or agreed to be allotted and issued by our Directors pursuant to such general

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

mandate of an amount representing the aggregate nominal value of our Shares purchased by our Company pursuant to the mandate to purchase Shares referred to in paragraph (iv) above (up to 10% of the aggregate nominal value of our Shares in issue immediately following the completion of the [REDACTED]); and

- (vi) all of the issued and unissued Series A-1 Preferred Shares and Series A-2 Preferred Shares in the authorized share capital of our Company be and are hereby re-designated and re-classified as ordinary Shares with a par value of US\$0.00002 each on a one for one basis upon and with effect from the [REDACTED]; and
- (c) our Company conditionally approved and adopted the Memorandum and Articles of Association with effect from the [REDACTED].]

[Each of the general mandates referred to in paragraphs (b)(iii), (b)(iv) and (b)(v) above will remain in effect until whichever is the earliest of:

- the conclusion of the next annual general meeting of our Company;
- the expiration of the period within which the next annual general meeting of our Company is required to be held by any applicable law or the Articles; or
- the time when such mandate is revoked or varied by an ordinary resolution of the Shareholders in a general meeting.]

5. Repurchase of our own securities

The following paragraphs include, among others, certain information required by the Stock Exchange to be included in this document concerning the repurchase of our own securities.

(a) *Provision of the Listing Rules*

The Listing Rules permit companies with a primary listing on the Stock Exchange to repurchase their own securities on the Stock Exchange subject to certain restrictions, the most important of which are summarized below:

(i) *Shareholder's approval*

All proposed repurchases of securities (which must be fully paid up in the case of shares) by a company with a primary listing on the Stock Exchange must be approved in advance by an ordinary resolution of the shareholders in a general meeting, either by way of general mandate or by specific approval of a particular transaction.

Pursuant to a resolution passed by our Shareholders on [●], the Repurchase Mandate was given to our Directors authorizing them to exercise all powers of our Company to repurchase Shares on the Stock Exchange, or on any other stock exchange on which the securities of our Company may be listed and which is recognized by the SFC and the Stock Exchange for this purpose, with a total nominal value up to 10% of the aggregate nominal value of our Shares in issue immediately following the completion of the [REDACTED] with such mandate to expire at the earliest of (i) the conclusion of the next annual general meeting of our Company (unless otherwise renewed by an ordinary

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

resolution of our Shareholders in a general meeting, either unconditionally or subject to conditions), (ii) the expiration of the period within which our Company's next annual general meeting is required by the Articles of Association or any other applicable laws to be held, and (iii) the date on which it is varied or revoked by an ordinary resolution of our Shareholders in a general meeting.

(ii) Source of funds

Repurchases must be funded out of funds legally available for the purpose in accordance with the Memorandum and Articles and the applicable laws and regulations of Hong Kong and the Cayman Islands. A listed company may not repurchase its own securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time. As a matter of Cayman Islands law, any repurchases by our Company may be made out of profits or out of the proceeds of a new issue of shares made for the purpose of the repurchase or from sums standing to the credit of our share premium account or out of capital, if so authorized by the Articles and subject to the Cayman Companies Act. Any premium payable on the repurchase over the par value of the shares to be repurchased must have been provided for out of profits or from sums standing to the credit of our share premium account or out of capital, if so authorized by the Articles and subject to the Cayman Companies Act.

(iii) Trading restrictions

The total number of shares which a listed company may repurchase on the Stock Exchange is the number of shares representing up to a maximum of 10% of the aggregate number of shares in issue.

A company may not issue or announce a proposed issue of new securities for a period of 30 days immediately following a repurchase (other than an issue of securities pursuant to an exercise of warrants or similar instruments requiring the company to issue securities which were outstanding prior to such repurchase) without the prior approval of the Stock Exchange. In addition, a listed company is prohibited from repurchasing its shares on the Stock Exchange if the purchase price is 5% or more than the average closing market price for the five preceding trading days on which its shares were traded on the Stock Exchange. The Listing Rules also prohibit a listed company from repurchasing its securities if the repurchase would result in the number of listed securities which are in the hands of the public falling below the relevant prescribed minimum percentage as required by the Stock Exchange. A listed company is required to procure that the broker appointed by it to effect a repurchase of securities discloses to the Stock Exchange such information with respect to the repurchase as the Stock Exchange may require.

(iv) Status of repurchased Shares

The listing of all repurchased securities (whether on the Stock Exchange or otherwise) is automatically canceled and the relative certificates must be canceled and destroyed. Under the laws of the Cayman Islands, unless, prior to the repurchase the directors of our Company resolve to hold the shares repurchased by our Company as treasury shares, shares repurchased by our Company shall be treated as canceled and the amount of our Company's issued share capital shall be diminished by the nominal value of those shares. However, the repurchase of shares will not be taken as reducing the amount of the authorized share capital under Cayman Islands laws.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

(v) Suspension of repurchase

A listed company may not make any repurchase of securities after a price sensitive development has occurred or has been the subject of a decision until such time as the price sensitive information has been made publicly available. In particular, during the period of one month immediately preceding the earlier of (a) the date of the board meeting (as such date is first notified to the Stock Exchange in accordance with the Listing Rules) for the approval of a listed company's results for any year, half-year, quarterly or any other interim period (whether or not required under the Listing Rules) and (b) the deadline for publication of an announcement of a listed company's results for any year or half-year under the Listing Rules, or quarterly or any other interim period (whether or not required under the Listing Rules), the listed company may not repurchase its shares on the Stock Exchange other than in exceptional circumstances. In addition, the Stock Exchange may prohibit a repurchase of securities on the Stock Exchange if a listed company has breached the Listing Rules.

(vi) Reporting requirements

Certain information relating to repurchases of securities on the Stock Exchange or otherwise must be reported to the Stock Exchange not later than 30 minutes before the earlier of the commencement of the morning trading session or any pre-opening session on the following Business Day. In addition, a listed company's annual report is required to disclose details regarding repurchases of securities made during the year, including a monthly analysis of the number of securities repurchased, the purchase price per share or the highest and lowest price paid for all such repurchases, where relevant, and the aggregate prices paid.

(vii) Core connected persons

The Listing Rules prohibit a company from knowingly purchasing securities on the Stock Exchange from a "core connected person", that is, a director, chief executive or substantial shareholder of the company or any of its subsidiaries or a close associate of any of them (as defined in the Listing Rules) and a core connected person shall not knowingly sell his securities to the company.

(b) *Reasons for repurchases*

Our Directors believe that it is in the best interests of our Company and our Shareholders for our Directors to have a general authority from the Shareholders to enable our Company to repurchase Shares in the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share or earnings per Share and will only be made where our Directors believe that such repurchases will benefit our Company and our Shareholders.

(c) *Funding of repurchases*

Repurchase of the Shares must be funded out of funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands.

Our Directors may not repurchase the Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange. Subject to the foregoing, our Directors may make repurchases out of profits of our Company or out of the share premium account of our Company or out of the proceeds of a new issuance of shares made

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

for the purpose of the repurchase or, if authorized by the Articles and subject to the Cayman Companies Act, out of capital and, in the case of any premium payable on the repurchase, out of profits of our Company or from sums standing to the credit of the share premium account of our Company or, if authorized by the Articles and subject to the Cayman Companies Act, out of capital.

However, our Directors do not propose to exercise the general mandate to such an extent as would, in the circumstances, have a material adverse effect on the working capital requirements of our Company or its gearing levels which, in the opinion of our Directors, are from time to time appropriate for our Company.

(d) *General*

The exercise in full of the Repurchase Mandate, on the basis of [REDACTED] Shares in issue immediately following the completion of the [REDACTED], excluding any Shares which may be issued pursuant to the exercise of the [REDACTED], could accordingly result in up to approximately [REDACTED] Shares being repurchased by our Company during the period prior to the earliest of:

- the conclusion of the next annual general meeting of our Company unless renewed by an ordinary resolution of our Shareholders in a general meeting, either unconditionally or subject to conditions;
- the expiration of the period within which our Company's next annual general meeting is required by the Articles of Association or any other applicable laws to be held; or
- the date on which it is varied or revoked by an ordinary resolution of our Shareholders in a general meeting.

None of our Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their associates currently intends to sell any Shares to our Company.

Our Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the Repurchase Mandate in accordance with the Listing Rules and the applicable laws in the Cayman Islands.

If, as a result of any repurchase of Shares, a Shareholder's proportionate interest in the voting rights of our Company increases, such increase will be treated as an acquisition for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of our Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. Save as aforesaid, our Directors are not aware of any consequences which would arise under the Takeovers Code as a consequence of any repurchases pursuant to the Repurchase Mandate.

Any repurchase of Shares that results in the number of Shares held by the public being reduced to less than 25% of the Shares then in issue could only be implemented if the Stock Exchange agreed to waive the Listing Rules requirements regarding the public shareholding referred to above. It is believed that a waiver of this provision would not normally be granted other than in exceptional circumstances.

No core connected person of our Company has notified our Company that he or she has a present intention to sell Shares to our Company, or has undertaken not to do so, if the Repurchase Mandate is exercised.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of material contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by members of our Group within the two years preceding the date of this document and are or may be material:

- (a) (i) the subscription agreement dated October 28, 2020 entered into among our Company, MicroPort Scientific Corporation, MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司) and Biolink Limited, as supplemented by (ii) the amendment agreement dated December 21, 2020 entered into among our Company, MicroPort Scientific Corporation, MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司), Biolink Limited and Biolink NT Investment Limited, and (iii) its second amendment agreement dated April 27, 2021 entered into among our Company, MicroPort Scientific Corporation, MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd., Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司), Biolink Limited and Biolink NT Investment Limited in relation to the issue of convertible bonds (the “**Convertible Bonds**”) to Biolink Limited and Biolink NT Investment Limited in a principal amount of US\$50 million and US\$20 million, respectively;
- (b) a share subscription and purchase agreement dated November 10, 2021 entered into among our Company, MicroPort NeuroTech Medical LTD, MicroPort NeuroTech International Limited, Shanghai Shenjing Vortex Medical Technology Co., Ltd., MicroPort NeuroTech (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司), MicroPort Scientific Investment LTD, CICC Healthcare Investment Opportunities V Limited, Nectar Neuro Limited, BVF III (BVI) Holding L.P., Biolink Healthcare Investment Limited, Star Wave Ventures Limited and Always Enterprises Limited, pursuant to which (i) CICC Healthcare Investment Opportunities V Limited, Nectar Neuro Limited, BVF III (BVI) Holding L.P., Biolink Healthcare Investment Limited, Star Wave Ventures Limited and Always Enterprises Limited (the “Investors”) agreed to subscribe for 2,032,495 newly issued Series A-2 Preferred Shares at an aggregate total consideration of US\$31,259,773 and (ii) MicroPort Scientific Investment LTD agreed to transfer 7,720,432 ordinary Shares to the Investors at an aggregate total consideration of US\$118,740,244;
- (c) a convertible note conversion agreement dated November 19, 2021 entered into among our Company, Biolink Limited and Biolink NT Investment Limited, pursuant to which, after the completion of the 2021 Pre-[REDACTED] Investment, the Convertible Bonds will be simultaneously converted to an aggregate of 11,759,125 Series A-1 Preferred Shares at a conversion price of approximately US\$5.95 per Series A-1 Preferred Share and our Company will allot and issue 8,399,375 Series A-1 Preferred Shares to Biolink Limited and 3,359,750 Series A-1 Preferred Shares to Biolink NT, respectively;
- (d) a capital increase agreement dated July 24, 2020 entered into among MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司), MicroPort (Shanghai) Medical Technology Investment Co., Ltd. (微創(上海)醫療科學投資有限公司), Shanghai Henian Investment Management Center (Limited Partnership) (上海鶴年投資管理中心(有限合夥)), Shanghai Wangdaotong Biotechnology Co., Ltd. (上海望道通生物技術有限公司) and Shanghai Lianghong Enterprise Management Consulting Center (Limited Partnership) (上海良弘企業管理諮詢中心(有限合夥)), pursuant to which Shanghai Wangdaotong Biotechnology Co., Ltd. (上海望道通生物技術有限公司) and Shanghai Lianghong Enterprise Management Consulting Center (Limited Partnership) (上海良弘企業管理諮詢中心(有限合夥)) agreed to make a capital injection of RMB115.0 million and RMB35.0 million to MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司), respectively;
- (e) an equity interest transfer agreement dated March 30, 2021 entered into among Shanghai Wangdaotong Biotechnology Co., Ltd. (上海望道通生物技術有限公司), Shanghai Lianghong Enterprise Management Consulting Center (Limited Partnership) (上海良弘企業管理諮詢中心(有限合夥)) and Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司), pursuant to which Shanghai Wangdaotong Biotechnology Co., Ltd. (上海望道通生物技術有限公司) and Shanghai Lianghong Enterprise Management Consulting Center (Limited Partnership) (上海良弘企業管理諮詢中心(有限合夥)) agreed to transfer their respective equity interest of 12.1053% and 3.6842% in MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司) to Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司) at a consideration of RMB115.0 million and RMB35.0 million, respectively;
- (f) a capital increase agreement dated May 10, 2021 entered into among MicroPort (Shanghai) Medical Technology Investment Co., Ltd. (微創(上海)醫療科學投資有限公司), Shanghai Henian Investment Management Center (Limited Partnership) (上海鶴年投資管理中心(有限合夥)) and Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司), pursuant to which Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司) agreed to make a capital contribution of RMB100 million to MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技(上海)有限公司);

APPENDIX IV STATUTORY AND GENERAL INFORMATION

- (g) an equity interest transfer agreement dated August 6, 2021 entered in to among MicroPort (Shanghai) Medical Technology Investment Co., Ltd. (微創(上海)醫療科學投資有限公司), Shanghai Henian Investment Management Center (Limited Partnership) (上海鶴年投資管理中心 (有限合夥)) and Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司), pursuant to which MicroPort Group Co., Ltd. (上海微創投資控股有限公司) and Shanghai Henian Investment Management Center (Limited Partnership) (上海鶴年投資管理中心 (有限合夥)) agreed to transfer an aggregate of approximately 27.1538% and 5.5616% of the equity interest in MicroPort NeuroTech Medical Technology (Shanghai) Co., Ltd. (微創神通醫療科技 (上海) 有限公司) at a total consideration of RMB161.022034 million and RMB32.980288 million to Shanghai Shenjing Vortex Medical Technology Co., Ltd. (上海神晶漩渦醫療科技有限公司), respectively;
- (h) [REDACTED]
- (i) [REDACTED]
- (j) [REDACTED]

2. Intellectual property rights

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:







No.	Trademark	Place of Registration	Registration Number	Class	Registered Owner	Registration Date	Expiry Date
1.	Tubridge.	PRC	56304809	10	MP NeuroTech Shanghai	November 28, 2021	November 27, 2031
2.	NUMEN	PRC	56295869	10	MP NeuroTech Shanghai	November 28, 2021	November 27, 2031
3.	U-track	PRC	56289139	10	MP NeuroTech Shanghai	November 28, 2021	November 27, 2031
4.	神雕飞燕	PRC	55704461	10	MP NeuroTech Shanghai	November 21, 2021	November 20, 2031
5.	神晶漩渦	PRC	54810429	10	MP NeuroTech Shanghai	October 28, 2021	October 27, 2031
6.	神晶漩渦	PRC	54780872	35	MP NeuroTech Shanghai	October 28, 2021	October 27, 2031
7.	神通脑医学	PRC	52247827	35	MP NeuroTech Shanghai	October 7, 2021	October 6, 2031
8.	Fastrack	PRC	52166186	10	MP NeuroTech Shanghai	August 28, 2021	August 27, 2031
9.	Diveer	PRC	51133342	10	MP NeuroTech Shanghai	August 21, 2021	August 20, 2031
10.	醉神通	PRC	48384389	41	MP NeuroTech Shanghai	March 14, 2021	March 13, 2031
11.	NeuroGuard	PRC	48380759	10	MP NeuroTech Shanghai	March 14, 2021	March 13, 2031
12.	Rebridge	PRC	48370798	10	MP NeuroTech Shanghai	March 14, 2021	March 13, 2031

APPENDIX IV













STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registration Number	Class	Registered Owner	Registration Date	Expiry Date
13.		PRC	48364278	41	MP NeuroTech Shanghai	April 7, 2021	April 6, 2031
14.	NEUROHAWK	PRC	48065382	10	MP NeuroTech Shanghai	February 28, 2021	February 27, 2031
15.	Numen	PRC	45808730	10	MP NeuroTech Shanghai	December 14, 2020	December 13, 2030
16.	NumenFR	PRC	45801984	10	MP NeuroTech Shanghai	December 14, 2020	December 13, 2030
17.	神通	PRC	45458582	10	MP NeuroTech Shanghai	November 28, 2020	November 27, 2030
18.	Fastrack	PRC	39975875	10	MP NeuroTech Shanghai	July 14, 2021	July 13, 2031
19.	MicroFill	PRC	39746775	10	MP NeuroTech Shanghai	April 21, 2020	April 20, 2030
20.	U-Track	PRC	38770679	10	MP NeuroTech Shanghai	March 21, 2020	March 20, 2030
21.	tubridge	PRC	36316038	35	MP NeuroTech Shanghai	October 21, 2019	October 20, 2029
22.	willis	PRC	36314194	44	MP NeuroTech Shanghai	October 21, 2019	October 20, 2029
23.	Tigertriever	PRC	32010061	35	MP NeuroTech Shanghai	April 7, 2019	April 6, 2029
24.	Tigertriever	PRC	31999843	10	MP NeuroTech Shanghai	April 7, 2019	April 6, 2029
25.	Apollo	PRC	31091477	10	MP NeuroTech Shanghai	August 14, 2020	August 13, 2030
26.	MicroFinish	PRC	29984616	10	MP NeuroTech Shanghai	January 28, 2019	January 27, 2029
27.	T-TRACK	PRC	20866932	10	MP NeuroTech Shanghai	September 28, 2017	September 27, 2027
28.		PRC	19687606	10	MP NeuroTech Shanghai	June 7, 2017	June 6, 2027
29.		PRC	19238963	10	MP NeuroTech Shanghai	October 21, 2018	October 20, 2028
30.	BRIDGE	PRC	15012956	10	MP NeuroTech Shanghai	November 7, 2015	November 6, 2025
31.	神通	PRC	11144110	37	MP NeuroTech Shanghai	November 14, 2013	November 13, 2023
32.	神通	PRC	11143904	5	MP NeuroTech Shanghai	November 21, 2013	November 20, 2023
33.		PRC	11134108	10	MP NeuroTech Shanghai	April 7, 2014	April 6, 2024
34.	神通	PRC	11134107	44	MP NeuroTech Shanghai	November 28, 2013	November 27, 2023
35.	APOLLO	PRC	10920358	10	MP NeuroTech Shanghai	April 7, 2015	April 6, 2025
36.	Trump	PRC	10318110	10	MP NeuroTech Shanghai	February 21, 2013	February 20, 2023
37.	Tubridge	PRC	9060772	10	MP NeuroTech Shanghai	January 28, 2022	January 27, 2032
38.		PRC	6171764	10	MP NeuroTech Shanghai	December 28, 2019	December 27, 2029

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registration Number	Class	Registered Owner	Registration Date	Expiry Date
39.	WILLIS	PRC	6079231	10	MP NeuroTech Shanghai	December 7, 2019	December 6, 2029
40.	微爱神通	PRC	56995009	36	MP NeuroTech Shanghai	December 21, 2021	December 20, 2031
41.	numen silk	PRC	56972585	10	MP NeuroTech Shanghai	December 21, 2021	December 20, 2031
42.	醉神通	PRC	48373527	35	MP NeuroTech Shanghai	December 28, 2021	December 27, 2031
43.		PRC	55123882	10	MP NeuroTech Shanghai	December 28, 2021	December 27, 2031
44.	numen nest	PRC	56983923	10	MP NeuroTech Shanghai	December 28, 2021	December 27, 2031
45.	numen uni	PRC	56983926	10	MP NeuroTech Shanghai	December 28, 2021	December 27, 2031
46.	Tubridge+	PRC	57843625	10	MP NeuroTech Shanghai	February 7, 2022	February 6, 2032
47.	Tubridge+	PRC	57855881	35	MP NeuroTech Shanghai	January 28, 2022	January 27, 2032
48.	Tubridge plus	PRC	57837585	10	MP NeuroTech Shanghai	February 7, 2022	February 6, 2032
49.	Tubridge plus	PRC	57842500	35	MP NeuroTech Shanghai	January 21, 2022	January 20, 2032
50.		PRC	48380882	35	MP NeuroTech Shanghai	February 28, 2022	February 27, 2032
51.	神雕飞燕	PRC	55721776	35	MP NeuroTech Shanghai	February 14, 2022	February 13, 2032
52.	神通医疗	PRC	57656147	10	Shendun Medical	January 28, 2022	January 27, 2032
53.	神通	PRC	57653280	10	Shendun Medical	January 28, 2022	January 27, 2032
54.	神通医疗	PRC	57667398	35	Shendun Medical	February 7, 2022	February 6, 2032
55.	神泓	PRC	58360900	10	Shendun Medical	February 7, 2022	February 6, 2032
56.	神泓	PRC	58353309	35	Shendun Medical	February 7, 2022	February 6, 2032
57.	Numen Silk	PRC	60275532	10	MP NeuroTech Shanghai	April 28, 2022	April 27, 2032
58.		Hong Kong	305781916	10	Our Company	October 25, 2021	October 24, 2031
59.		Hong Kong	305781916	35	Our Company	October 25, 2021	October 24, 2031
60.		Hong Kong	305781925	10	Our Company	October 25, 2021	October 24, 2031
61.		Hong Kong	305781925	35	Our Company	October 25, 2021	October 24, 2031

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registration Number	Class	Registered Owner	Registration Date	Expiry Date
62.		Hong Kong	305781943	10	Our Company	October 25, 2021	October 24, 2031
63.		Hong Kong	305781943	35	Our Company	October 25, 2021	October 24, 2031
64.		Hong Kong	305543019	10	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
65.		Hong Kong	305543019	35	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
66.		Hong Kong	305543028	10	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
67.		Hong Kong	305543028	35	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
68.		Hong Kong	305543037	10	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
69.		Hong Kong	305543037	35	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
70.		Hong Kong	305543046	10	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
71.		Hong Kong	305543046	35	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
72.		Hong Kong	305543055	10	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
73.		Hong Kong	305543055	35	MP NeuroTech Shanghai	February 23, 2021	February 22, 2031
74.	Numen	Taiwan	02143871	10	MP NeuroTech Shanghai	June 1, 2021	May 31, 2031
75.	NumenFR	Taiwan	02143872	10	MP NeuroTech Shanghai	June 1, 2021	May 31, 2031
76.	NumenFR	European Union (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registration Number	Class	Registered Owner	Registration Date	Expiry Date
77.	NumenFR	United Kingdom (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
78.	NumenFR	Russia (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
79.	NumenFR	India (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
80.	NumenFR	Brazil (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
81.	NumenFR	Japan (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
82.	Numen	European Union (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
83.	Numen	United Kingdom (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
84.	Numen	Russia (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
85.	Numen	India (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
86.	Numen	Brazil (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
87.	Numen	Japan (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020	August 25, 2030
88.	<i>Tübridge</i>	Japan	5546887	10	MP NeuroTech Shanghai	December 28, 2012	December 28, 2022
89.	<i>Tübridge</i>	European Union	011018801	10	MP NeuroTech Shanghai	July 05, 2012	July 05, 2022
90.	<i>Tübridge</i>	United Kingdom	UK00911018801	10	MP NeuroTech Shanghai	July 05, 2012	July 05, 2022

As of the Latest Practicable Date, we had applied for the registration of the following trademarks which consider to be or may be material to our business:

No.	Trademark	Place of Application	Application Number	Class	Applicant	Application Date
1.	DIVEER	PRC	60296427	10	MP NeuroTech Shanghai	November 2, 2021
2.	X-track	PRC	60285326	10	MP NeuroTech Shanghai	November 2, 2021
3.	x-track	PRC	58719878	10	MP NeuroTech Shanghai	August 24, 2021
4.	守护神	PRC	45788527	10	MP NeuroTech Shanghai	April 26, 2020


APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Application	Application Number	Class	Applicant	Application Date
5.	NeuroHawk	PRC	62267249	10	MP NeuroTech Shanghai	January 19, 2022
6.	Neuro-Skyline	PRC	62502530	41	MP NeuroTech Shanghai	February 8, 2022
7.	Neuro-Horizon	PRC	62490966	41	MP NeuroTech Shanghai	February 8, 2022
8.	NumenFR	United States (subsequently designated by Madrid)	1556806	10	MP NeuroTech Shanghai	March 21, 2021
9.	NumenFR	Canada (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020
10.	NumenFR	Korea (designated by Madrid)	1556806	10	MP NeuroTech Shanghai	August 25, 2020
11.	Numen	United States (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	March 21, 2021
12.	Numen	Canada (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020
13.	Numen	Korea (designated by Madrid)	1556829	10	MP NeuroTech Shanghai	August 25, 2020

As of the Latest Practicable Date, we had been granted by Shanghai MicroPort Medical the rights to use the following registered trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of Registration	Registration Number	Class	Registered Proprietor	Date of registration	Expiry Date	License Method
1.	 MicroPort 微创神通科技	PRC	14303623	10	Shanghai MicroPort Medical	May 14, 2015	May 13, 2025	Exclusive license
2.	微创神通	PRC	44551717	10	Shanghai MicroPort Medical	November 21, 2020	November 20, 2030	Exclusive license
3.	 MicroPort NeuroTech	PRC	14303636	10	Shanghai MicroPort Medical	July 21, 2016	July 20, 2026	Exclusive license
4.	 MicroPort NeuroTech	United States	1235101	10	Shanghai MicroPort Medical	January 26, 2016	January 26, 2026	Exclusive license
5.		PRC	1362015	10	Shanghai MicroPort Medical	February 7, 2020	February 6, 2030	Non-exclusive license
6.	MicroPort	PRC	13246289	10	Shanghai MicroPort Medical	June 7, 2015	June 6, 2025	Non-exclusive license
7.		PRC	13981362	10	Shanghai MicroPort Medical	October 14, 2015	October 13, 2025	Non-exclusive license

As of the Latest Practicable Date, we had been granted by Shanghai MicroPort Medical the rights to use the following trademarks that had been applied for registration which we consider to be or may be material to our business:

No.	Trademark	Place of Application	Application Number	Class	Applicant	Application Date	License Method
1.	神通	PRC	41705351	10	Shanghai MicroPort Medical	October 17, 2019	Exclusive license
2.	Neurotech	PRC	51315916	10	Shanghai MicroPort Medical	November 16, 2020	Exclusive license
3.	 MicroPort 微创神通	PRC	56263433	10	Shanghai MicroPort Medical	May 21, 2021	Exclusive license

APPENDIX IV STATUTORY AND GENERAL INFORMATION

(b) *Patents*

As of the Latest Practicable Date, we owned the following granted patents which we consider to be or may be material to our business:

No.	Patent	Type	Registration Number	Registered Owner	Place of Registration	Expiry Date
1.	Embolization Device and Coil Therefor (栓塞裝置及其彈簧圈)	Invention	ZL2018111702379	MP NeuroTech Shanghai	PRC	October 9, 2038
2.	Coil and Preparation Method Therefor (彈簧圈及其製備方法)	Invention	ZL2016110731676	MP NeuroTech Shanghai	PRC	November 29, 2036
3.	An Intravascular Stent (一種血管支架)	Invention	ZL2015101334771	MP NeuroTech Shanghai	PRC	March 25, 2035
4.	A Coil and Preparation Method Therefor (一種彈簧圈及其製備方法)	Invention	ZL2013107514321	MP NeuroTech Shanghai	PRC	December 31, 2033
5.	Thrombectomy Apparatus and Thrombectomy Device (取栓器及取栓裝置)	Invention	ZL2013100564635	MP NeuroTech Shanghai	PRC	February 21, 2033
6.	Graft Thickness Control System, including Grafting Machine and Graft Thickness Control Method Therefor (覆膜厚度控制系統、包括其的覆膜機以及覆膜厚度控制方法)	Invention	ZL2012104583683	MP NeuroTech Shanghai	PRC	November 14, 2032
7.	A Coagulant and Endovascular Thrombectomy Device (一種凝固劑和血管內取栓裝置)	Invention	ZL201210191643X	MP NeuroTech Shanghai	PRC	June 12, 2032
8.	Intracranial Vascular Thrombectomy Device (顱內血管取栓裝置)	Invention	ZL2012101488704	MP NeuroTech Shanghai	PRC	May 14, 2032
9.	Intracranial Vascular Thrombectomy Device (顱內血管取栓裝置)	Invention	ZL2012101488901	MP NeuroTech Shanghai	PRC	May 14, 2032
10.	Intracranial Vascular Thrombectomy Device (顱內血管取栓裝置)	Invention	ZL2012101488973	MP NeuroTech Shanghai	PRC	May 14, 2032
11.	A Double Balloon Catheter for Thrombolysis (一種用於溶栓的雙球囊導管)	Invention	ZL2012101064232	MP NeuroTech Shanghai	PRC	April 12, 2032
12.	Intravascular Stent with Improved Visualization Performance and Method for Enhancing Visualization Performance of Intravascular Stent (改進顯影性能的血管支架及增強血管支架顯影性能的方法)	Invention	ZL2011102348839	MP NeuroTech Shanghai	PRC	August 15, 2031
13.	Graft Device (一種覆膜設備)	Invention	ZL201110129984X	MP NeuroTech Shanghai	PRC	May 18, 2031
14.	A Microcatheter (一種微導管)	Invention	ZL2011100618640	MP NeuroTech Shanghai	PRC	March 15, 2031
15.	Liquid Embolic Material Composite and Preparation Method Therefor (液體栓塞材料組合物及其製備方法)	Invention	ZL2010106091010	MP NeuroTech Shanghai	PRC	December 27, 2030
16.	An Embolic Material Composite and Preparation Method Therefor (一種栓塞材料組合物及其製備方法)	Invention	ZL2010102671017	MP NeuroTech Shanghai	PRC	August 27, 2030
17.	An Embolic Material and Preparation Method Therefor (一種栓塞材料及其製備方法)	Invention	ZL2010102671021	MP NeuroTech Shanghai	PRC	August 27, 2030
18.	An Embolic Agent and Preparation Method Therefor (一種栓塞劑及其製備方法)	Invention	ZL2010102671163	MP NeuroTech Shanghai	PRC	August 27, 2030
19.	An Embolic Material Composite and Preparation Method Therefor (一種栓塞材料組合物及其製備方法)	Invention	ZL2010102492426	MP NeuroTech Shanghai	PRC	August 10, 2030
20.	Surgical Apparatus for Aneurysms (一種動脈瘤手術裝置)	Invention	ZL2010101164481	MP NeuroTech Shanghai	PRC	March 2, 2030
21.	A Medical Guide Wire (一種醫用導絲)	Invention	ZL2010101091349	MP NeuroTech Shanghai	PRC	February 5, 2030
22.	A Medical Guide Wire (一種醫用導絲)	Invention	ZL2009102480676	MP NeuroTech Shanghai	PRC	December 30, 2029
23.	A Vascular Reconstruction Stent (一種血管重構支架)	Invention	ZL2009101946880	MP NeuroTech Shanghai	PRC	August 27, 2029
24.	A Microcatheter (一種微導管)	Invention	ZL2009100542095	MP NeuroTech Shanghai	PRC	June 30, 2029
25.	Intravascular Stent for Repairing Intravascular Lesions (用於病變血管修補的血管支架)	Invention	ZL2008102028542	MP NeuroTech Shanghai	PRC	November 15, 2028
26.	Graft stent (覆膜支架)	Invention	ZL2008100408087	MP NeuroTech Shanghai	PRC	July 17, 2028

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registration Number	Registered Owner	Place of Registration	Expiry Date
27.	An Endoluminal Stent with Nested Structure (一種嵌套式結構的人體管腔內支架)	Invention	ZL2007100471226	MP NeuroTech Shanghai	PRC	October 17, 2027
28.	Delivery Guidewire (輸送導絲)	Utility model	ZL2021200920837	MP NeuroTech Shanghai	PRC	January 13, 2031
29.	A Delivery Guidewire and Therapeutic Device (A Delivery Guidewire and Therapeutic Device (一種輸送導絲及治療裝置))	Utility model	ZL201922079490X	MP NeuroTech Shanghai	PRC	November 27, 2029
30.	Vertebral Stent (椎動脈支架)	Utility model	ZL2017206976810	MP NeuroTech Shanghai	PRC	June 15, 2027
31.	Coil Detachment Controller (彈簧圈解脫控制器)	Design	ZL2020305515937	MP NeuroTech Shanghai	PRC	September 16, 2030
32.	A Guiding Catheter (一種導引導管)	Invention	ZL2013107497646	Shentu Medical	PRC	December 31, 2033
33.	A Coil and Preparation Method Therefor (一種彈簧圈及其製備方法)	Invention	ZL2013107514270	Shendun Medical	PRC	December 31, 2033
34.	EMBOLISM COIL CONVEYING DEVICE AND PREPARATION METHOD THEREFOR	Invention	US11172934	MP NeuroTech Shanghai	United States	September 4, 2038
35.	Thrombectomy device and thrombectomy device	Invention	EP2959853	MP NeuroTech Shanghai	EPO	February 21, 2034
36.	THROMBEKT OMIEVORRICHTUNG UND AUSRÜSTUNG FÜR THROMBEKTOMIE	Invention	EP2959853	MP NeuroTech Shanghai	Germany	February 21, 2034
37.	DISPOSITIF DE THROMBECTOMIE ET ÉQUIPEMENT DE THROMBECTOMIE	Invention	EP2959853	MP NeuroTech Shanghai	France	February 21, 2034
38.	Thrombectomy device and thrombectomy equipment	Invention	EP2959853	MP NeuroTech Shanghai	United Kingdom	February 21, 2034
39.	Surgical Apparatus for Aneurysms	Invention	EP2543345	MP NeuroTech Shanghai	EPO	March 2, 2031
40.	CHIRURGISCHE VORRICHTUNG FÜR ANEURYSMEN	Invention	EP2543345	MP NeuroTech Shanghai	Germany	March 2, 2031
41.	INSTRUMENT CHIRURGICAL POUR LES ANÉVRISMES	Invention	EP2543345	MP NeuroTech Shanghai	France	March 2, 2031
42.	Surgical apparatus for aneurysms	Invention	EP2543345	MP NeuroTech Shanghai	United Kingdom	March 2, 2031
43.	Aparato quirúrgico para aneurismas	Invention	ES2697513	MP NeuroTech Shanghai	Spain	March 2, 2031
44.	DISPOSITIVO CHIRURGICO PER ANEURISMI.	Invention	EP2543345	MP NeuroTech Shanghai	Italy	March 2, 2031
45.	Surgical Apparatus for Aneurysms	Invention	JP5814949	MP NeuroTech Shanghai	Japan	March 2, 2031
46.	Embolism coil conveying device and preparation method therefor	Invention	JP7026779	MP NeuroTech Shanghai	Japan	August 9, 2038
47.	SURGICAL APPARATUS FOR ANEURYSMS	Invention	KR1014985310000	MP NeuroTech Shanghai	Korea	March 2, 2031
48.	Embolism coil conveying device and preparation method therefor	Invention	KR10-2365255	MP NeuroTech Shanghai	Korea	August 9, 2038
49.	SURGICAL APPARATUS FOR ANEURYSMS	Invention	IN325833	MP NeuroTech Shanghai	India	March 2, 2031
50.	Medical Guide Wire	Invention	EP2532381	MP NeuroTech Shanghai	EPO	January 25, 2031
51.	MEDIZINISCHER FÜHRUNGSDRAHT	Invention	EP2532381	MP NeuroTech Shanghai	Germany	January 25, 2031
52.	FIL-GUIDE MÉDICAL	Invention	EP2532381	MP NeuroTech Shanghai	France	January 25, 2031
53.	Medical Guide Wire	Invention	EP2532381	MP NeuroTech Shanghai	United Kingdom	January 25, 2031
54.	MEDICAL GUIDE WIRE	Invention	JP6116911	MP NeuroTech Shanghai	Japan	January 25, 2031
55.	Micro Catheter	Invention	EP2450077	MP NeuroTech Shanghai	EPO	June 17, 2030
56.	MIKROKATHETER	Invention	EP2450077	MP NeuroTech Shanghai	Germany	June 17, 2030
57.	MICROCATHÉTER	Invention	EP2450077	MP NeuroTech Shanghai	France	June 17, 2030
58.	Micro Catheter	Invention	EP2450077	MP NeuroTech Shanghai	United Kingdom	June 17, 2030

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registration Number	Registered Owner	Place of Registration	Expiry Date
59.	DUAL GUIDE WIRE DISTAL PROTECTION DEVICE	Invention	EP1882490	MP NeuroTech Shanghai	EPO	December 1, 2025
60.	DISTALER SCHUTZFILTER EINES DOPPELTEN FÜHRUNGSDRAHTES	Invention	EP1882490	MP NeuroTech Shanghai	Germany	December 1, 2025
61.	FILTRE DE PROTECTION DISTAL A DOUBLE FIL GUIDE	Invention	EP1882490	MP NeuroTech Shanghai	France	December 1, 2025
62.	DUAL GUIDE WIRE DISTAL PROTECTION DEVICE	Invention	EP1882490	MP NeuroTech Shanghai	United Kingdom	December 1, 2025

As of the Latest Practicable Date, we had applied for the following patent applications which we consider to be or may be material to our business:

No.	Patent	Type	Application Number	Applicant	Place of Registration	Application Date
1.	A Pusher, Detachment Device and Medical Device (一種推送杆、解脫裝置及醫用裝置)	Invention	CN2021114597395	MP NeuroTech Shanghai	PRC	December 2, 2021
2.	Embolization Device and Embolization System (栓塞裝置以及栓塞系統)	Invention	CN2021110468520	MP NeuroTech Shanghai	PRC	September 8, 2021
3.	Medical Implant and Preparation Method Therefor (醫療植入物及其製備方法)	Invention	CN2021106047054	MP NeuroTech Shanghai	PRC	May 31, 2021
4.	Delivery Guidewire and Preparation Method Therefor (輸送導絲及其製造方法)	Invention	CN2021100420741	MP NeuroTech Shanghai	PRC	January 13, 2021
5.	An Intravascular Implant and Therapeutic Device (一種血管植入物及醫療設備)	Invention	CN2021106741591	MP NeuroTech Shanghai	PRC	January 6, 2021
6.	Hemangioma Occlusion Device, Hemangioma Occlusion Therapeutic Device and Hemangioma Occlusion System (血管瘤封堵裝置、血管瘤封堵治療裝置和血管瘤封堵系統)	Invention	CN2020108991737	MP NeuroTech Shanghai	PRC	August 31, 2020
7.	An Intravascular Stent (一種血管支架)	Invention	CN2020106150474	MP NeuroTech Shanghai	PRC	June 30, 2020
8.	Imaging Structure, Stent and Thrombectomy System (顯影結構、支架及取栓系統)	Invention	CN2020106211088	MP NeuroTech Shanghai	PRC	June 30, 2020
9.	Electrolytic Detachment Coil Pusher End Structure and Detachment System and Embolization System Therefor (電解脫彈簧圈推送杆端部結構及其解脫系統、栓塞系統)	Invention	CN2020106180658	MP NeuroTech Shanghai	PRC	June 30, 2020
10.	A Catheter (一種導管)	Invention	CN2020106226435	MP NeuroTech Shanghai	PRC	June 30, 2020
11.	Detachment Device, System and Method, and Therapeutic Device (解脫裝置、系統及方法、治療裝置)	Invention	CN2020105066015	MP NeuroTech Shanghai	PRC	June 5, 2020
12.	Detachment Device, Detachment System and Detachment Method, and Therapeutic Device (解脫裝置、解脫系統及解脫方法、治療裝置)	Invention	CN2020105066299	MP NeuroTech Shanghai	PRC	June 5, 2020
13.	Flow Choking Catheter (阻流導管)	Invention	CN2019113344490	MP NeuroTech Shanghai	PRC	December 23, 2019
14.	A Delivery Guidewire and Therapeutic Device (一種輸送導絲及治療裝置)	Invention	CN2019111837830	MP NeuroTech Shanghai	PRC	November 27, 2019
15.	Intravascular Implant, Delivery Device and Medical Equipment (血管植入物、輸送裝置及醫療設備)	Invention	CN201910580250X	MP NeuroTech Shanghai	PRC	June 28, 2019
16.	Electrolytic Detachment Mechanism and Electrolytic Detachment Device (電解脫機構以及電解脫裝置)	Invention	CN2018111702576	MP NeuroTech Shanghai	PRC	September 30, 2018
17.	Medical Stent and Forming Method Therefor (醫用支架及其形成方法)	Invention	CN2018108269635	MP NeuroTech Shanghai	PRC	July 25, 2018

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Application Number	Applicant	Place of Registration	Application Date
18.	Stent, Interventional Medical Device and Interventional Medical System (支架、介入醫療裝置以及介入醫療系統)	Invention	CN2018104050370	MP NeuroTech Shanghai	PRC	April 28, 2018
19.	An Embolism and Preparation Method Therefor (一種栓塞物及其製備方法)	Invention	CN2020116245729	Shendun Medical	PRC	December 31, 2020
20.	An Embolism and Preparation Method Therefor (一種栓塞物及其製備方法)	Invention	CN2020116245790	Shendun Medical	PRC	December 31, 2020
21.	A Preparation Method for Catheter and Catheter Transition Structure (一種導管和導管過渡結構的製備方法)	Invention	PCT/ CN2021/132608	MP NeuroTech Shanghai	WIPO	November 24, 2021
22.	Medical Catheter and Preparation Method Therefor (醫用導管及其製備方法)	Invention	PCT/ CN2021/132607	MP NeuroTech Shanghai	WIPO	November 24, 2021
23.	An Embolism and Preparation Method Therefor (一種栓塞物及其製備方法)	Invention	PCT/ CN2021/130763	Shendun Medical	WIPO	November 15, 2021
24.	An Embolism and Preparation Method Therefor (一種栓塞物及其製備方法)	Invention	PCT/ CN2021/130762	Shendun Medical	WIPO	November 15, 2021
25.	Balloon Catheter (球囊導管)	Invention	PCT/ CN2021/125445	MP NeuroTech Shanghai	WIPO	October 21, 2021
26.	Catheter and Flow Choking Catheter (導管和阻流導管)	Invention	PCT/ CN2021/125444	MP NeuroTech Shanghai	WIPO	October 21, 2021
27.	Hemangioma Occlusion Device, Hemangioma Occlusion Therapeutic Device and Hemangioma Occlusion System (血管瘤封堵裝置、血管瘤封堵治療裝置和血管瘤封堵系統)	Invention	PCT/ CN2021/112627	MP NeuroTech Shanghai	WIPO	August 13, 2021
28.	Hemangioma Occlusion Device, Hemangioma Occlusion Therapeutic Device and Hemangioma Occlusion System (血管瘤封堵裝置、血管瘤封堵治療裝置和血管瘤封堵系統)	Invention	PCT/ CN2021/112628	MP NeuroTech Shanghai	WIPO	August 13, 2021
29.	Hemangioma Occlusion Device, Hemangioma Occlusion Therapeutic Device and Hemangioma Occlusion System (血管瘤封堵裝置、血管瘤封堵治療裝置和血管瘤封堵系統)	Invention	PCT/ CN2021/112629	MP NeuroTech Shanghai	WIPO	August 13, 2021
30.	An Intravascular Stent (一種血管支架)	Invention	PCT/ CN2021/112630	MP NeuroTech Shanghai	WIPO	August 13, 2021
31.	A Catheter (一種導管)	Utility model	PCT/ CN2021/111916	MP NeuroTech Shanghai	WIPO	August 10, 2021
32.	Electrolytic Detachment Coil Pusher End Structure and Detachment System and Embolization System Therefor (電解脫彈簧圈推送杆端部結構及其解脫系統、栓塞系統)	Invention	PCT/ CN2021/110686	MP NeuroTech Shanghai	WIPO	August 4, 2021
33.	Imaging Structure, Stent and Thrombectomy System (顯影結構、支架及取栓系統)	Invention	PCT/ CN2021/113545	MP NeuroTech Shanghai	WIPO	August 19, 2021
34.	Detachment Device, System and Method, and Therapeutic Device (解脫裝置、系統及方法、治療裝置)	Invention	PCT/ CN2021/108016	MP NeuroTech Shanghai	WIPO	July 23, 2021
35.	Detachment Device, Detachment System and Detachment Method, and Therapeutic Device (解脫裝置、解脫系統及解脫方法、治療裝置)	Invention	PCT/CN/ 2021108015	MP NeuroTech Shanghai	WIPO	July 23, 2021
36.	Catheter Fixation Device and Catheter Protection Device (管固定裝置和導管保護裝置)	Invention	PCT/ CN2022/072971	MP NeuroTech Shanghai	WIPO	January 20, 2022
37.	Flow Choking Catheter (阻流導管)	Invention	US17460950	MP NeuroTech Shanghai	United States	August 30, 2021

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Application Number	Applicant	Place of Registration	Application Date
38.	A Delivery Guidewire and Therapeutic Device (一種輸送導絲及治療裝置)	Invention	US17409085	MP NeuroTech Shanghai	United States	August 23, 2021
39.	A Delivery Guidewire and Therapeutic Device (一種輸送導絲及治療裝置)	Invention	PCT/ CN2020/112448	MP NeuroTech Shanghai	WIPO	August 31, 2020
40.	Flow Choking Catheter (阻流導管)	Invention	US17460869	MP NeuroTech Shanghai	United States	August 30, 2021
41.	Flow Choking Catheter (阻流導管)	Invention	US17460821	MP NeuroTech Shanghai	United States	August 30, 2021
42.	A Medical Balloon, Balloon Catheter and Medical Device (一種醫用球囊、球囊導管及醫療裝置)	Invention	PCT/ CN2020/096642	MP NeuroTech Shanghai	WIPO	June 17, 2020
43.	Intravascular Implant, Delivery Device and Medical Equipment (血管植入物、輸送裝置及醫療設備)	Invention	PCT/ CN2020/098312	MP NeuroTech Shanghai	WIPO	June 26, 2020
44.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	EP19870690	MP NeuroTech Shanghai	EPO	October 8, 2019
45.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	US17283456	MP NeuroTech Shanghai	United States	October 8, 2019
46.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	RU2021112128	MP NeuroTech Shanghai	Russia	October 8, 2019
47.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	CA3116066	MP NeuroTech Shanghai	Canada	October 8, 2019
48.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	KR1020217013509	MP NeuroTech Shanghai	Korea	October 8, 2019
49.	EMBOLISM DEVICE AND SPRING COILS THEREOF	Invention	JP2021520110	MP NeuroTech Shanghai	Japan	October 8, 2019
50.	ELECTRICAL DETACHMENT MECHANISM AND ELECTRICAL DETACHMENT DEVICE	Invention	EP19866573	MP NeuroTech Shanghai	EPO	September 20, 2019
51.	ELECTRICAL DETACHMENT MECHANISM AND ELECTRICAL DETACHMENT DEVICE	Invention	US17281111	MP NeuroTech Shanghai	United States	September 20, 2019
52.	ELECTRICAL DETACHMENT MECHANISM AND ELECTRICAL DETACHMENT DEVICE	Invention	JP2021542245	MP NeuroTech Shanghai	Japan	September 20, 2019
53.	ELECTRICAL DETACHMENT MECHANISM AND ELECTRICAL DETACHMENT DEVICE	Invention	KR1020217013011	MP NeuroTech Shanghai	Korea	September 20, 2019
54.	EMBOLISM COIL CONVEYING DEVICE AND PREPARATION METHOD THEREFOR	Invention	EP18847082	MP NeuroTech Shanghai	EPO	August 9, 2018
55.	Intravascular Implant, Delivery Device and Medical Equipment (血管植入物、輸送裝置及醫療設備)	Invention	US17617884	MP NeuroTech Shanghai	United States	June 26, 2020
56.	Intravascular Implant, Delivery Device and Medical Equipment (血管植入物、輸送裝置及醫療設備)	Invention	EP208322495	MP NeuroTech Shanghai	EPO	June 26, 2020

(c) **Domain names**

As of the Latest Practicable Date, we owned the following domain name which we consider is material to our business:

No.	Domain name	Registered Owner	Expiry Date
1.	medneurotech.com	MP NeuroTech Shanghai	August 30, 2023

APPENDIX IV STATUTORY AND GENERAL INFORMATION

(d) Copyrights

As of the Latest Practicable Date, we had registered the following software copyright:

No.	Software copyright	Registered owner	Registration number	Place of registration	Registration date
1.	NeuroTech implant release control software (神通植入物解脱控制軟體)	MP NeuroTech Shanghai	2021SR0326761	PRC	March 3, 2021

Save as aforesaid, as of the Latest Practicable Date, there were no other intellectual property rights which we consider to be or may be material to our business.

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Particulars of Directors’ service contracts and appointment letters

(a) Executive Directors

Each of our executive Directors [has entered into] a service contract with our Company. The initial term of their respective service contract shall commence from the date of his/her appointment as a Director and continue for a period of three years after or until the third annual general meeting of our Company since the [REDACTED], whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the Articles), until terminated in accordance with the terms and conditions of the service contract or by either party giving to the other not less than three months’ prior notice in writing.

(b) Non-executive Directors and Independent non-executive Directors

Each of our non-executive Directors and independent non-executive Directors has entered into an appointment letter with our Company. The initial term for their appointment letters shall commence from the date of his/her appointment as a Director and continue for a period of three years after or until the third annual general meeting of our Company since the [REDACTED], whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the Articles), until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months’ prior notice in writing.

2. Remuneration of Directors

The aggregate remuneration (including fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payment) paid to our Directors for each of the three years ended December 31, 2021 was approximately RMB4.3 million, RMB4.6 million and RMB6.5 million, respectively.

Under the arrangement currently in force, the aggregate remuneration (including fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and equity-settled share-based payment) of our Directors for the year ending December 31, 2022 is estimated to be no more than approximately RMB5.3 million (excluding discretionary bonus).

3. Disclosure of interests

(a) Interests and Short Positions of Our Directors and the Chief Executive of Our Company in the Share Capital of our Company and Its Associated Corporations Following Completion of the [REDACTED]

Immediately following completion of the [REDACTED] (assuming the [REDACTED] is not exercised and each Preferred Share will be converted to one Share upon the [REDACTED] becoming unconditional), the interests or short positions of our Directors and chief executives in the Shares, underlying shares and debentures of our Company and its associated corporations, within the meaning of Part XV of the SFO, which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/ she is taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules, will be as follows:

(i) Long positions in the shares and underlying shares of our associated corporations

Name of Directors	Name of associated corporation	Nature of interest	Percentage of shareholding in the associated corporation
Mr. Peng Bo	MicroPort	Beneficial owner ⁽¹⁾	0.42%
	MicroPort CardioFlow	Beneficial owner ⁽²⁾	<0.1%
	Medtech Corporation (微創心通醫療科技有限公司) (“MicroPort CardioFlow”)		
Mr. Xie Zhiyong	MicroPort	Beneficial owner ⁽³⁾	<0.1%
Mr. Wang Yiqun Bruce	MicroPort	Beneficial owner ⁽⁴⁾	<0.1%

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Notes:

- (1) As of the Latest Practicable Date, Mr. Peng Bo was interested in (i) 869,496 shares of MicroPort; and (ii) 6,841,170 underlying shares of MicroPort by virtue of the options granted to him under a share option scheme of MicroPort.
- (2) As of the Latest Practicable Date, Mr. Peng Bo was interested in 54,304 shares of MicroPort CardioFlow.
- (3) As of the Latest Practicable Date, Mr. Xie Zhiyong was interested in (i) 638,851 shares of MicroPort; and (ii) 546,883 underlying shares of MicroPort by virtue of the options granted to him under a share option scheme of MicroPort.
- (4) As of the Latest Practicable Date, Mr. Wang Yiqun Bruce was interested in 405,620 shares of MicroPort.

(b) *Interests and Short Positions Discloseable under Divisions 2 and 3 of Part XV of the SFO*

For information on the persons who will, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and each Preferred Share will be converted to one Share upon the [REDACTED] becoming unconditional), having or be deemed or taken to have beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of any other member of our Company, see “Substantial Shareholders” in this document.

Save as disclosed in the section headed “Substantial Shareholders” in this document, our Directors were not aware of any persons who would, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and each Preferred Share will be converted to one Share upon the [REDACTED] becoming unconditional), having or be deemed or taken to the beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of any member of our Group or had option in respect of such capital.

4. Disclaimers

- (a) Save as disclosed in “—C. Further Information about Our Directors and Substantial Shareholders—1. Particulars of Directors’ service contracts and appointment letters” in this appendix, there are no existing or proposed service contracts (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)) between our Directors and any member of our Group;
- (b) none of our Directors or the experts named in the paragraph headed “—D. Other Information—4. Qualifications and consents of experts” in this Appendix has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (c) save as disclosed in the section headed “[REDACTED]” in this document, or in connection with the [REDACTED], none of our Directors nor any of the experts named in the paragraph headed “—D. Other Information—4. Qualifications and consents of experts” in this Appendix is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group as a whole;
- (d) save as disclosed in the section headed “Substantial Shareholders” in this document and “—C. Further Information about Our Directors and Substantial Shareholders—3. Disclosure of Interests” in this appendix, taking no account of any Shares which may be taken up under the [REDACTED], so far as is known to any Director or chief executive of our Company, no other person (other than a Director or chief executive of our Company) will, immediately following completion of the [REDACTED], have interests or short positions in the Shares and underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or (not being a member of our Group), be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group;
- (e) save as disclosed in “—C. Further Information about Our Directors and Substantial Shareholders—3. Disclosure of Interests” in this appendix, none of our Directors or chief executive of our Company has any interests or short positions in the Shares, underlying shares or debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be entered into the register referred to therein, or will be required, pursuant to the Model Code for Securities Transaction by Directors of Listed Issuers, to be notified to our Company and the Stock Exchange once the Shares are [REDACTED] thereon;

APPENDIX IV STATUTORY AND GENERAL INFORMATION

- (f) save as disclosed in “[REDACTED]—Joint Sponsors’ Independence” in this document and save in connection with the [REDACTED], none of the experts named in the paragraph headed “—D. Other Information—4. Qualifications and consents of experts” in this Appendix: (i) is interested legally or beneficially in any of our Shares or any shares in any of our subsidiaries; or (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group; and
- (g) save as disclosed in “Business—Raw Materials and Our Suppliers—Suppliers” in this document, none of our Directors or their respective close associates or any Shareholders of our Company (who to the knowledge of our Directors owns more than 5% of the number of our issued shares) has any interest in our five largest suppliers or our five largest customers.

D. OTHER INFORMATION

1. Estate duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

As of the Latest Practicable Date, our Directors were not aware of any litigation, arbitration proceedings or claim of material importance is pending or threatened against any member of our Group that could have a material adverse effect on our financial condition or results of operations.

3. Joint Sponsors

The Joint Sponsors [have made] an application on our behalf to the Stock Exchange for the [REDACTED] of, and permission to [REDACTED], the Shares in issue, the Shares to be issued pursuant to the [REDACTED] (including the additional Shares which may fall to be issued pursuant to exercise of the [REDACTED] (if any)). All necessary arrangements [have been made] to enable such Shares to be admitted into [REDACTED].

Each of the Joint Sponsors will be paid by our Company a fee of US\$[REDACTED] to act as a sponsor to our Company in connection with the [REDACTED].

4. Qualifications and consents of experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

<u>Name</u>	<u>Qualification</u>
J.P. Morgan Securities (Far East) Limited	Licensed under the SFO to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO
China International Capital Corporation Hong Kong Securities Limited	Licensed under the SFO to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO
KPMG	Certified Public Accountants under Public Interest Entity Auditor registered in accordance with the Financial Reporting Council Ordinance
Maples and Calder (Hong Kong) LLP	Legal advisers as to Cayman Islands laws
Jia Yuan Law Offices	Legal advisers as to PRC laws
China Insights Industry Consultancy Limited	Industry consultant

Save as disclosed in “[REDACTED]—Joint Sponsors’ Independence” in this document and save in connection with the [REDACTED], as of the Latest Practicable Date, none of the experts named above had any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

5. Binding effect

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies Ordinance so far as applicable.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

6. No material and adverse change

Our Directors believe that there has been no material or adverse change in the financial or trading or prospects of our Group since September 30, 2021 (being the date to which the latest audited consolidated financial statements of our Group were prepared).

7. Bilingual document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

8. Preliminary expenses

We have not incurred any material preliminary expenses in relation to the incorporation of our Company.

9. Promoters

We have no promoter for the purpose of the Listing Rules.

Save as disclosed in the sections headed “History, Reorganization and Corporate Structure” and “Financial Information” in this document, within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoters in connection with the [REDACTED] and the related transactions described in this document.

10. Miscellaneous

(a) Within the two years immediately preceding the date of this document:

- (i) save as disclosed in “—A. Further Information about Our Group —2. Changes in the share capital of our Company” and “—A. Further Information about Our Group—3. Change in the share capital of our subsidiaries” in this appendix, neither we nor any of our subsidiaries has issued or agreed to issue any share or loan capital fully or partly paid up either for cash or for a consideration other than cash;
- (ii) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (iii) save as disclosed in the section headed “[REDACTED]” in this document, no commissions, discounts, brokerage or other special terms have been granted in connection with the issue or sale of any shares or loan capital of any member of our Group;
- (iv) save as disclosed in the section headed “[REDACTED]” in this document, no commission has been paid or payable to any persons for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any shares of our Company or any of our subsidiaries;
- (v) no founder, management or deferred shares of our Company or any of our subsidiaries have been issued or agreed to be issued;
- (vi) our Company has no outstanding convertible debt securities or debentures; and
- (vii) there is no arrangement under which future dividends are waived or agreed to be waived or is agreed conditionally or unconditionally to be put under option;

(b) our Directors confirm that there has not been any interruption in the business of our Company which may have or have had a material and adverse effect on the financial position of our Company in the 12 months immediately preceding the date of this document;

(c) the principal register of members of our Company will be maintained by our [REDACTED], [REDACTED], in the Cayman Islands and our Hong Kong branch register of members will be maintained by our [REDACTED], [REDACTED], in Hong Kong. Unless our Directors otherwise agree, all transfer and other documents of title of Shares must be lodged for registration with and registered by our [REDACTED] and may not be lodged in the Cayman Islands; and

(d) save as disclosed in “Summary—The Spin-Off” and “History, Reorganization and Corporate Structure—Spin-off of Our Group from MicroPort” in this document, no company within our Group is presently listed on any stock exchange or traded on any trading system and no listing or permission to deal is being or is proposed to be sought.